[ Syntimmune raises $50M in Series B ]

Founded in 2013, Syntimmune is a biotechnology company that focuses on FcRn biology for the treatment of IgG-mediated autoimmune diseases.

Thenew financing will further advance Syntimmune’s clinical development program, which includes two ongoing Phase 1b/2a clinical trials of the company’s lead drug candidate, SYNT001, in pemphigus and warm autoimmune hemolytic anemia, support further preclinical development of SYNT002, as well as additional research activities.

[Junction Investments] will allow crowdfunding for Hollywood

Thanks to new securities rules, Hollywood is about to get into the crowdfunding game. A startup, Junction Investments, plans to open for business on Wednesday, allowing wealthy individuals to.. on 28 Mar 2014

[Small e-commerce] spends on television campaign

News, data and statement included in FundingSMEs are intended exclusively for information purposes. No data or statement in FundingSMEs is or should be considered a recommendation for the purchase, retention, or sale of the securities referred to herein. FundingSMEs accepts no liability for the consequences of the reader's reliance on these news, data or statements and disclaims any intent to make securities or securities markets recommendations.

Note: It looks like JavaScript is disabled in your browser. Some elements of this form may require JavaScript to work properly. If you have trouble submitting the form, try enabling JavaScript momentarily and resubmit. JavaScript settings are usually found in Browser Settings or Browser Developer menu.